December 21, 2009 |
| PKTX is Reviewing Major European Proposals |
VANCOUVER--(BUSINESS WIRE)--ProtoKinetix Inc. (PKTX) has been approached by a European biopharma investment group with a series of proposals to develop commercial partnerships in the pharmaceutical/cosmetic arenas. In order to support these initiatives, it has been strongly suggested that our European technology (AAGP™) should be more visibly showcased within the European community. This would include an awareness program leading up to a sponsorship for a listing on the AIM, London Stock Exchange.
ProtoKinetix believes that these events are natural synergies due to the strong European origins of the AAGP™ family of molecules. AAGP™ was first created in the laboratories of the University of Rouen, France. Human embryonic stem cell preservation was successfully tested at the University of Helsinki, Finland. The University of Bordeaux proved the ability of AAGP™ to defend skin cells from a wide range of hostile conditions. The National Institute of Chemistry, in France, showed that these molecules were non-toxic in standard concentrations.
ProtoKinetix’ President and CEO states that, “in addition to the proposals currently being evaluated, the company has a number of excellent opportunities to enter into new collaborations with world leading biotechnology investigators and companies to expand the use and applications of the AAGP™ family of molecules. Though these European collaborations and partnerships, we are confident of both financial and scientific success”.
About ProtoKinetix
ProtoKinetix, Inc. is a biotechnology company that has developed and patented a family of synthetic anti-aging glycoproteins (AAGP™) for medicine and the biotechnology and cosmetic industries. PKTX is currently in dialogue with major corporations and institutions who have contacted the company about the broad range of applications for AAGP™ products.
| PROTOKINETIX, INC Stock Symbol :: PKTX |
|
 | PROTOKINETIX, INC (PKTX) ProtoKinetix, Inc. is a biotechnology company that has developed and patented a family of synthetic anti-aging glycopeptides AAGP™ for medicine and the biotechnology and cosmetic industries. | |||||||||||
ProtoKinetix, Inc. 2225 Folkestone Way West Vancouver, BC V7S 2Y6 Phone: 604-926-6627 Fax: 604-926-6632 http://www.protokinetix.com |
· MIGENIX Inc. (MIGENIX) is a biopharmaceutical company engaged in the research, development and commercialization of drugs for the treatment of infectious diseases. The Company's programs include drug candidates for the treatment and prevention of hospital-acquired and other infections, the treatment of dermatological diseases, the treatment of chronic hepatitis C infections and the treatment of hepatitis B infections.OTCBB:MGIFF Recent Price: $.042 · Oncolytics Biotech Inc. (Oncolytics) is a development stage biopharmaceutical company that focuses on the discovery and development of pharmaceutical products for the treatment of cancers that have not been successfully treated with conventional therapeutics. The Company is focused on the research and development of one product, REOLYSIN, for human application. REOLYSIN is the Company’s potential cancer therapeutic. Its products under development have not been manufactured on a commercial scale. NASDAQ:ONCY Recent Price: $2.88 |
| Current Projects |
 | L'Oreal Independently Validates ProtoKinetix' AAGP™ Cosmetic ProtoKinetix recently announced that L’Oreal (LOR) has applied for a patent using the ProtoKinetix’ Anti-Aging Glyco Peptide (AAGP™) family of molecules as the basis for a skin lightening agent. This application had already been identified by PKTX as one of the many cosmetic applications included in its patents. If L’Oreal’s patent application were to be successful, they would have to negotiate a license agreement with PKTX to commercialize the use of AAGP™ in any product. This patent application by L’Oreal strongly supports the tremendous potential of AAGPs. | ProtoKinetix’ Advisory Boards Launch Major Commericial Initiatives for It's AAGPs ProtoKinetix’ Business Advisory Board Chairman, Dr. Edward Martin, recently reported on progress implemented by the Corporate Advisory Boards. In addition to the several major corporations currently evaluating AAGP™, the Advisory Boards have been able to successfully present the ProtoKinetix family of anti-agingglycopeptides to several senior pharmaceutical executives. These initiatives are predominantly structured to build partnering/ licensing relationships using AAGP™ in medical therapies and regenerative medicine. |
| Company Overview |
| ProtoKinetix, Inc. (OTCBB: PKTX) ProtoKinetix is a biotech company focused on developing and licensing patented anti-aging glycopeptides (AAGP™) to the health care, biotechnology and skin care/cosmetic industries. Since 2005, ProtoKinetix has been engaged in groundbreaking scientific research. Several recent tests and trials on ProtoKinetix’ AAGP™ cryopreservation (freezing cells to -196°C) has shown promising results across multiple cell lines. AAGP™ molecules have demonstrated to enhance the health and extend the life of cells and seem to carry anti-inflammatory properties. ProtoKinetix is the first company to make a stable and non-toxic version. With a versatile biotechnology platform in place, ProtoKinetix has entered into discussions with a number small and large, Fortune 500 companies to bring life-enhancing AAGP™ containing products to market. In September 2008, ProtoKinetix announced its first commercial contract to manufacture AAGP™ as the primary active ingredient in an anti-inflammatory sports cream in the US. This contract is one of several in the pipeline that is positioning ProtoKinetix on a path of rapid revenue growth and commercial success. Patented Technology AAGP™s were invented by ProtoKinetix Director of Science Dr. Geraldine Castelot-Deliencourt, and was developed and protected by patents in partnership with the Institute for Scientific Application of France. For her work in this area, Dr. Castelot-Deliencourt was honored in 2006 with France’shighest award for scientific accomplishment – the Francinov Award. Dr. Castelot-Deliencourt achieved what was previously thought to be the impossible. She created a stable, non-toxic and synthetic version of AFGP (Anti-Freeze Glycoprotein), a compound naturally produced by some fish, insects, reptiles, bacteria and plants that enable cell survival in freezing temperatures. The substances that prevent these organisms from freezing were isolated, characterized and designated as antifreeze glycoproteins or AFGPs. The overall effect of the lab-created version of AFGP, trademarked by ProtoKinetix as AAGP™, is to protect, preserve and in some cases to repair living cells. ProtoKinetix is a pioneer in the clinical testing of AAGP™ in North America and Europe. Under the direction of Dr. Castelot-Deliencourt, AAGP™ has shown anti-inflammatory effects and appears to improve the health and extend the lifespan of cells. TF Chem, a state-of-the-art lab headed by Dr. Castelot-Deliencourt in France, successfully developed a prototype derivative of AAGP™. This derivative extends ProtoKinetix’ intelletual property by significantly enhancing the already powerful preservative characteristics of AAGP™. This new structure has the potential to increase AAGP™ bioactivity by a factor of over one hundred times, enabling AAGP™ to be applied at lower concentrations in each application. These low levels of concentration will be of vital importance across all segments of pharmaceutical, cell therapy, blood preservation and skin care industries. Minimal concentration requirements of AAGP™ will also enable ProtoKinetix to enter into new therapeutic applications. Commercial Applications The extent of the value of the ProtoKinetix family of AAGPs™ is being investigated by companies and ProtoKinetix is targeting commercial entities specializing in regenerative medicine, cellular and tissue therapies, organ transplantation, trauma, blood product banking, anti- inflammation and cosmetics/skin care. Skincare and Cosmetics In an article on September 22, 2008, Euromonitor International analyst Virgina Lee pointed out five trends driving the overall growth of the global skin care market: an aging population; increased wealth in emerging markets like China, India and Latin America; pursuit of agelessness; technological advances; and massive awareness of health & wellness. These trends are creating a robust world skin care market, which posted sales of $65.7 billion in 2007, up 40% from 2002 and up 7% from 2006. Facial care, nourishers/anti-agers are growing the fastest, with sales of $14.9 billion in 2007, up 67% from 2002. Increased demand from aging baby boomers, combined with strong market acceptance of Botox, Retinol and other biochemical-based ingredients, bodes well for ProtoKinetix planned entry into highly targeted, global skin care and cosmetics markets. AAGP™ is an ideal active ingredient for anti-inflammatory and anti-aging skin care lotions. When AAGP™ is combined with Coenzyme Q10, a powerful anti-oxidant effect is achieved that protects and also helps the cells repair previously existing damage. In vitro laboratory tests have shown the AAGP™ molecules can protect in vitro skin cells from damage and prevent the death of cells that would otherwise occur from UV rays and free radicals. AAGP™ appears to protect in vitro skin cells from cold temperatures, oxidation, UV irradiation and pH variations. Health Care Health Care Applications of AAGP™ fall into two main categories: (1) harvesting, storage and transplanting cells, tissues and organs; and (2) treatments for conditions and disease caused by stress factors, including UV radiation, oxidation and inflammation. Inflammation and oxidation are both well-known causes of life-threatening conditions and diseases, as well as accelerated aging. In addition, many acute medical problems are benefiting from cell therapies and transplantation of cell, tissues and organs. AAGP™ is now being used or investigated as a possible solution by many healthcare companies that specialize in medical cell therapies, organ transplant, trauma, blood product banking and anti-inflammation. ProtoKinetix expects to license several commercial applications from its AAGP™ family as well as expand its ongoing R&D with institutions and businesses. ProtoKinetix is actively in talks with several healthcare companies that are testing the molecule in their specific niche applications. Stem Cell Research Stem cell research often precludes advancements in health care, and is considered one of most promising areas of R&D in biotechnology today. According to Research and Markets, the value of stem cell-therapy is projected to increase from $26.6 billion in 2005 to $56.2 billion in 2010 and $96.3 billion in 2015. Medical scientists believe that stem cells offer the potential to cure or mitigate a host of pervasive and debilitating diseases and conditions such as multiple sclerosis, Parkinson’s Alzheimer’s, and diabetes. They also believe that stem cells can be used to repair damaged tissuesor cells caused by caused by injuries to organs, limbs, and the spinal cord. A top tier company in the Umbilical Cord Blood Preservation (UCB) industry has conducted preliminary tests using AAGP™ as a protective agent in the cryofreezing and subsequent thawing of cord blood units. Post-thawing, those that had used a small concentration of AAGP™ showed a 104% average increase in yield compared to cells without AAGP™, and a function level 38% greater than the control group. UCB companies enable families to save their newborn’s cord blood for possible future medical use in the treatment of over 40-diseases, including blood cancers and genetic disease. Since a major loss of cells occurs in the transportation and storage of the cord blood prior to freezing, it has been suggested that AAGP™ be added to the cord blood bags before shipping. This could further assist in the increase of the viable cell population. In laboratory controlled tests, AAGP™-treated cells have survived harsh environmental stresses such as cryopreservation hydrogen peroxide oxidation, inflammation from interleukin 1Beta, UV-C radiation, and nutrient deprivation. Leadership Ross L. Senior, LLB, President and CEO In 2005, Mr. Senior co-founded Rowan All Natural Skin Care, Inc., a Canadian-based provider of skin care products for the health care profession. In 1988, Mr. Senior founded Ross L. Senior and Associates, a business and technology consulting firm, where he remained its principal from 1988 to 2005. He practiced law from 1974 to 1988 and appeared as a trial lawyer in various tribunals until 2005. |
| News |
|
No comments:
Post a Comment